Eli Lilly to acquire AtaiBeckley for $2.8 billion, signaling deeper bet on psychedelics
read at Endpoints ↗DealPositive
Eli Lilly announced on Thursday that it will acquire psychedelic drug developer AtaiBeckley. The purchase price is set at $2.8 billion paid upfront.
The sizable upfront payment highlights Lilly's strong commitment to expanding its portfolio in the emerging psychedelics space.
Industry observers see the deal as a clear sign that big pharmaceutical companies are moving from watching to actively investing in psychedelic therapies after years of cautious interest.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley”
read at Endpoints ↗82 words · retrieved Jul 16
comments(0)
5-min edit window · permanent after that